Hi women, can you post pictures or talk about your academic achievements? I need some motivation this month. If you see this tweet, share it so women can see it.

NewLimit plans to begin human trials for its cellular rejuvenation therapy in 2027. > NewLimit, a longevity biotechnology company co-founded by Brian Armstrong, has raised $435 million at a $3.1 billion valuation to advance one of the world’s most ambitious cellular rejuvenation programs into clinical testing. > The company uses partial epigenetic reprogramming, a method designed to restore youthful gene activity inside aging cells without changing the cell’s identity. > Their therapy uses mRNA encoding rejuvenating transcription factors delivered through lipid nanoparticles (LNPs), the same core delivery technology used in Moderna and BioNTech COVID-19 vaccines. > In preclinical studies, a single dose improved survival in alcohol-induced liver damage mouse models across multiple months of repeated alcohol exposure cycles. > Researchers observed that untreated old mice became heavily sedated after alcohol exposure, while treated old mice behaved more like young mice and remained active and resilient. > According to NewLimit, the mechanism is not about metabolizing alcohol faster, but about restoring the hepatocyte’s youthful resilience and regenerative capacity. > The therapy both prevented new liver damage and helped regenerate existing liver injury in aged animals. > The company’s first clinical target is age-related liver disease, but the same cellular reprogramming platform could eventually be expanded to immune aging, cardiovascular disease and other age-related disorders.